select trial semaglutide cardiovascular outcomes non-diabetic 2023 and by baseline and changes in adiposity measurements: a prespecified analysis of the A trial emulation in Nature

If water sounds unappealing, try sugar-free electrolyte drinks or clear broths

Medicare is prohibited under current law from covering drugs used for weight loss, but Medicare Part D plans can cover GLP-1s for their other medically-accepted indications, including to treat diabetes, and now to cut cardiovascular risk based on a recent memo from the Centers for Medicare & Medicaid Services (CMS)

Oral dosing differs from weekly injection dosing

Adding the Precision Peptide Genetic Test ($99 after your first month) reveals whether your insulin resistance pattern aligns with GLP-1 responsiveness, FTO gene variants affecting weight regulation, or MC4R pathway sensitivities that shape your metabolic needs